All posts by imreal

Vyne Named Among Top Healthcare Revenue Cycle Management Companies to Know in 2023


News Image

“Vyne‘s solutions work to bridge the information divide in healthcare and empower clients to achieve performance excellence,” said Steve Roberts, Chief Executive Officer at Vyne.

Vyne®, a company improving both medical and dental healthcare providers’ revenue cycles through high-performing and industry-leading communication and information exchange technology solutions, announced that the company has been named to Becker’s List of Healthcare Revenue Cycle Management Companies to Know in 2023.

Recognized for Vyne’s end-to-end platform that facilitates a secure environment for patients, providers, health plans and partners to communicate, Becker’s list also spotlighted that The National Association of Healthcare Access Management (NAHAM) previously honored Vyne with the Murray Rimmer award, acknowledging the company’s significant and substantial contribution to the development of access management in the healthcare industry.

“Vyne‘s solutions work to bridge the information divide in healthcare and empower clients to achieve performance excellence,” said Steve Roberts, Chief Executive Officer at Vyne. “By automating revenue cycle workflows, we aim to transform healthcare by improving financial performance and elevating patient care.”

Vyne is committed to delivering innovative technologies that help increase revenue while meeting and anticipating the needs of medical and dental clients through industry-leading health information collation, exchange, and claims management.

Visit Becker’s List of Healthcare Revenue Cycle Management Companies to Know in 2023 to view the complete list.

About Vyne:

Vyne® provides end-to-end health information exchange and electronic healthcare communication management for more than 800 hospitals and health systems, 75,000 dental offices, and more than 800 plans and payers across the United States. Uniquely positioned to serve multiple key stakeholders within healthcare, Vyne has made Inc. 5000’s annual list of the nation’s most prestigious and fastest-growing private companies for 15 consecutive years. Under Steve Roberts, Vyne continues leveraging synergies across its two health tech businesses, Vyne Medical and Vyne Dental, to accelerate growth and facilitate relationships between providers, payers and patients across the full healthcare spectrum.

© 2023 Napa EA/MEDX LLC. All rights reserved. All third-party trademarks and tradenames (including logos and icons) referenced are and remain the property of their respective owners. Hyperlinks included are provided for convenience and may lead to resources located on servers maintained by other persons or organizations. Vyne is not responsible for the privacy practices of third-party websites.

Share article on social media or email:

EBSCO Information Services Names Christina Barnes, MSN, RN, CPNP, Dynamic Health™ Section Editor in Pediatrics


News Image

We are looking to enhance Dynamic Health’s high-acuity pediatric collection to have the most extensive, current NICU and PICU content available at the point of care. Christina brings extensive pediatric experience to the team, adding a layer of oversight to help advance our content.

EBSCO Information Services (EBSCO), the preeminent provider of evidence-based clinical decision support resources, has appointed Christina Barnes, MSN, RN, CPNP, High-Acuity Pediatric Section Editor for Dynamic Health™. Dynamic Health is an evidence-based resource designed to help nurses and health care professionals master skills, obtain fast answers to clinical questions and foster evidence-based practice, helping to improve patient care.

Barnes is a board-certified Pediatric Nurse Practitioner with deep experience in pediatric and neonatal intensive care nursing. She is a graduate of John Hopkins School of Nursing and has served as a freelance writer for organizations including National Institutes of Health (NIH) and American Academy of Allergy Asthma and Immunology (AAAAI).

As High-Acuity Pediatrics Section Editor, Barnes will provide editorial oversight on the NICU and PICU content within Dynamic Health. Dynamic Health, which offers robust skill and competency development content, is expanding its high-acuity pediatric section, further aligning its content with neonatal and pediatric intensive care clinical practice guidelines and professional organization resources.

EBSCO Editor in Chief, Dynamic Health, Diane Hanson RN, BSN, MM, FNAP, says the addition of Christina Barnes to the editorial team will enhance the resource’s collection and bring a new perspective to its existing content. “We are looking to enhance Dynamic Health’s high-acuity pediatric collection to have the most extensive, current NICU and PICU content available at the point of care. Christina brings extensive pediatric experience to the team, adding a layer of oversight to help advance our content.”

For more information on Dynamic Health’s offerings, visit https://www.ebsco.com/health-care/products/dynamic-health.

About EBSCO Information Services

EBSCO Information Services (EBSCO) is the preeminent provider of online research content and search technologies serving academic, school and public libraries; healthcare and medical institutions; corporations; and government agencies around the world. EBSCO’s Clinical Decisions suite of products are designed to improve patient care by providing healthcare professionals with the most current, evidence-based answers to clinical questions as they arise at the point of care. For more information, visit the EBSCO website at: http://www.ebsco.com

For more information, please contact:

Jessica Holmes

Communications Director

jmholmes@ebsco.com

978-414-0240

Share article on social media or email:

INFINITT Healthcare Solutions Plays a Part in HIMSS DIAM Stage 7 Accreditation for First- in -the -World Medical Center


During its DIAM Stage 7 validation, HIMSS acknowledged SMC as a “world leader” in digital pathology.

Samsung Medical Center (SMC) is the first healthcare provider in the world to receive Stage 7 of the HIMSS digital imaging adoption model (DIAM) maturity model. A DIAM assesses a healthcare organization’s level of digital imaging maturity and provides guidelines for achieving full enterprise imaging.

INFINITT Healthcare Solutions are currently being used at SMC and were demonstrated in clinical settings during the onsite stage 7 validation. They are as follows:

  • INFINITT digital pathology solution: All pathology images are managed systematically in a seamless interface with the patient information from the EMR (APLIS), realizing a fully digital pathology imaging workflow and setting the foundation for wider usage of pathology images for various collaborative care and research purposes.
  • INFNITT clinical information solution (within the Cardiology Department): All kinds of non-DICOM patient images and multimedia data (such as EKG and EEG) are digitally captured using clinical information solutions (CIS). The system acquires data from all types of non-DICOM clinical devices and enables users to easily view, exchange, store, and manage whatever data they need directly from the EMR.
  • INFINITT smart endo (Department of Endoscopy): AI image analysis software enabling real-time, automatic detection and marking of polyps during colonoscopy exams. A certified Level II medical image detection aid software by South Korea’s Ministry of Food and Drug Safety (MFDS).

During the congratulatory speech, the HIMSS validation team commented, “Your digital pathology capabilities were world-class, your utilization of AI in clinical decision augmentation and support was very innovative,” said Julius Bogdan, VP of digital health advisory, HIMSS North America.

During its DIAM Stage 7 validation, HIMSS acknowledged SMC as a “world leader” in digital pathology. “This is the most comprehensive use of integrated digital pathology we have seen,” said Andrew Pearce, HIMSS VP analytics and global advisory lead, in Healthcare IT News.

Jean-Hyoung Lee, manager of IT infrastructure at SMC, shared his thoughts on the Stage 7 DIAM validation in Healthcare IT News, “[Becoming] the world’s first hospital to reach DIAM Stage 7 has great significance to us. It [shows] that our medical imaging information management system fully complies with international standards and is efficiently utilized with the patient’s health as the top priority.”

About INFINITT North America

INFINITT North America is a global enterprise imaging partner for medical institutions. They are a wholly owned subsidiary of INFINITT Healthcare, a global healthcare information technology company with world-class research and development capabilities and robust sub-specialty and multi-facility solutions. They have eight global business units — 20 regional partners — with a global customer base of more than 6,300 hospitals, imaging centers, and laboratories.

For more information, visit http://www.infinittna.com or email info@infinittna.com.

One platform. INFINITT possibilities.

Share article on social media or email:

Catalent Commences Construction of New $20M Expansion to its Clinical Supply Facility in Schorndorf, Germany


Our site in Schorndorf plays a key strategic role in our global clinical supply network, and this expansion will provide much needed capacity and capabilities to meet the growing needs of customers.

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has begun construction of a $20 million expansion project at its clinical supply facility in Schorndorf, Germany. A ground-breaking ceremony was recently attended by the Mayor of Schorndorf, Bernd Hornikel, as well as leaders from the facility and Catalent’s global Clinical Development and Supply team.

The project will see the site’s footprint increase by 32,000 square feet (3,000 square meters) to add capacity for the storage and handling of clinical trial supply materials at controlled room temperatures between 15 and 25 degrees Celsius, and creates space in the original building to accommodate the installation of a new, fully automatic bottle filling line, and a dedicated area for Catalent’s FastChain® demand-led supply service. Work on the site is expected to be completed by June 2024.

“Our site in Schorndorf plays a key strategic role in our global clinical supply network, and this expansion will provide much needed capacity and capabilities to meet the growing needs of customers,” said Ricky Hopson, President, Division Head for Clinical Development & Supply at Catalent. “Additional temperature-controlled handling, storage, and distribution means the facility is well-equipped to respond to the growing demand for clinical supply capacity and services in the region, including for products requiring cold chain support. Working closely with our adjacent oral dose manufacturing center of excellence, and our European development centers for oral, biologic, cell therapy and gene therapy products, customers have access to fully integrated development, clinical packaging, and distribution solutions.”

Opened in 1996, Catalent’s Schorndorf clinical supply facility provides comprehensive clinical supply services including multi-lingual project services – including English, French and German – comparator sourcing, primary and secondary packaging, labeling, clinical storage and distribution, and returns and destruction. The company’s FastChain demand-led supply service is a continuous GMP approach that decouples primary from secondary packaging to enable timely and cost-effective adaptation and regional supply of clinical materials.

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

Goliath Technologies Unveils AI-Powered Monitoring and Troubleshooting Assistant


News Image

“KIP is a game-changer for IT professionals.”

Goliath Technologies, a leader in end-user experience monitoring and troubleshooting software, today announced the introduction of KIP, an AI-powered monitoring and troubleshooting assistant. Powered by OpenAI/ChatGPT 4, KIP is designed to help IT professionals improve efficiency when monitoring and troubleshooting user experience issues.

KIP offers detailed insights on how to resolve complex IT issues, providing IT professionals with the guidance they need to get to the root cause of problems. Its learning is based on detailed guides and troubleshooting tips from Goliath and industry experts, ensuring that users have access to the latest information and best practices.

“KIP is a game-changer for IT professionals,” said Thomas Charlton, CEO of Goliath Technologies. “We understand the challenges that IT professionals face when it comes to monitoring and troubleshooting user experience issues, and KIP was developed with those challenges in mind. By leveraging the power of AI, KIP helps organizations improve efficiency across IT and mitigate impact from expertise and resource constraints.”

KIP is integrated into Goliath’s existing product suite, making it easy for users to access and use. This integration also increases time to resolution drastically, ensuring that IT professionals can quickly and efficiently resolve user experience issues.

“We’re thrilled to introduce KIP to the market,” said Edgar Zacharjev, VP of WW Marketing at Goliath Technologies. “By leveraging the power of OpenAI, we’ve created an AI-powered assistant that delivers real value to IT professionals. KIP is an essential tool for anyone who needs to monitor and troubleshoot user experience issues on Citrix and VMware Horizon environments, and we’re confident that it will become a go-to resource for IT teams everywhere.”

KIP offers Citrix and VMware Horizon expertise out of the box, ensuring that users have access to the latest insights and best practices for these popular platforms. It also provides detailed insights into user experience issues, giving IT professionals the information they need to quickly and efficiently resolve problems.

KIP is now available for limited testing through Goliath Technologies. For more information, visit [https://goliathtechnologies.com/kip/.

_________________

About Goliath Technologies

Goliath Technologies offers end-user experience monitoring and troubleshooting software, with embedded intelligence and automation, that enables IT pros to anticipate, troubleshoot, and document performance issues regardless of where workloads, applications, or users are located. By doing so, Goliath helps IT break out of reactive mode, and into proactive mode. Customers include Universal Health Services, NorthBay Healthcare, Enterprise Rent-A-Car, Penn National Insurance, American Airlines, Office Depot, Tech Mahindra, Pacific Life, Xerox, HCL, and others. Learn more about how we empower proactive IT at goliathtechnologies.com.

Share article on social media or email:

Navigate360 Doubles-Down on Efforts to End School Shootings, Teen Suicide and Bullying in US Schools


News Image

Navigate360, the nation’s leader in K–12 school safety and student wellness solutions, announces completion of phase one integration between PBIS Rewards Advanced Referral System (ARS) and their Behavior Intervention & Restorative Practices offering. This milestone comes four months post-acquisition, reinforcing Navigate360’s commitment to helping schools address safety and student wellness through a more seamless and holistic approach allowing educators and behavioral intervention staff to better serve the growing needs of student mental health and behavioral support.

Through the early identification of warning signs associated with a pathway to violence and self-harm, educators can get students back on a path to wellness, proactively protecting the entire school community. These early integration efforts are focused on enabling educators to quickly connect students with situationally relevant resources.

“In a time where teachers and school staff are carrying a heavy task to address learning loss, they are also tasked with simultaneously managing disruptive and concerning behavior that has accelerated post-pandemic,” said Navigate360 Chief Executive Officer, JP Guilbault. “According to EAB, nearly 60% of teachers reported that pressure to boost learning loss and academic outcomes left them with insufficient time to address increased behavioral issues within their classrooms. If we continue to let these issues go unresolved, we will continue to prevent our schools and teachers from getting to the business of learning. We must do better – for our educators and for our students.”

By simplifying the user experience within the PBIS Rewards ARS feature, users can assign recommended grade-appropriate Behavior Intervention lessons to specifically address the problem behavior documented in the referral. This expedites the school’s ability to turn discipline into a learning opportunity. It also promotes the natural connection between PBIS and SEL practices, providing additional opportunities to address student needs.

“Current systems are too fragmented and laden with manual processes for teachers and behavioral intervention teams, often resulting in staff dissatisfaction and limited results,” continued Guilbault. “We need to make systems easier, seamless and more informative. This release makes it easier for school staff to identify and assign age-appropriate lessons associated with minor and major behavior infractions that work in tandem with their PBIS, MTSS and Restorative Practices programs. By addressing early and low-level concerning behavior with ARS and Behavioral Intervention lessons, we are helping schools reduce repeat infractions – by up to 58% in some cases – and increasing both teaching and learning time.”

This connectivity is supported by research from the University of Illinois at Chicago, the Collaborative for Academic, Social and Emotional Learning (CASEL) and the University of Oregon’s Center on Positive Behavioral Intervention and Supports (PBIS) and shows how the alignment between PBIS and SEL can improve students’ emotional skills, academics and behavior.

As reported last month, across more than 33 million online school and social media alerts, new data from Navigate360 showed alerts related to self-harm up 51% year-over-year, as well as a 25% increase year-over-year in alerts related to weapons and harm to others. Additionally, more than 4,000 anonymous tips per week are coming into school tip lines, with the most common tips related to self-harm and weapons.

“Tragic events continue to erode the confidence of students, parents, teachers and school communities,” said Guilbault. “When we say ‘zero incidents’ at Navigate360, we don’t mean just mass shootings – we mean zero suicides, zero shootings and fatalities, zero acts of bullying, overdoses, dating violence, inappropriate adult-child relationships and more. This is what we strive for everyday – doing anything less is simply not an option.”

With this push for accelerated product integration, Navigate360 is one step closer in their pursuit of zero incidents. To learn more about Navigate360’s holistic suite of solutions that address school climate and culture, threat assessment and prevention, and safety management and preparedness, visit navigate360.com.

About Navigate360

Navigate360 is the premier provider of safety solutions for schools, leading to enhanced student wellbeing. With more than 20 years of experience, our multifaceted, layered approach—providing everything from curricula that support positive behavior and self-image to campus physical safety and personnel training—focuses on incident prevention. Currently, more than 14 million students are attending schools using Navigate360 solutions.

Share article on social media or email:

CellMax Life Announces Expansion of Company Board With Leading Industry Experts


CellMax Life: Stanley Lapidus (L) and Ronnie Andrews (R)

CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena.

“Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success,” said Atul Sharan, CEO of CellMax Life. Stan is one of the most successful innovators and leaders in cancer diagnostics, and it is a privilege to have him join CelMax’s advisory board. Ron’s scientific expertise and extensive background in commercializing diagnostic tests will greatly enable execution of the regulatory and marketing strategies for our FirstSight colorectal cancer screening blood test.”

Each new board member brings a wealth of experience:

  • Stan Lapidus is an inventor and entrepreneur who currently serves on a number of healthcare and medical technology boards. He was the founding CEO of three medical diagnostics companies: Cytyc Corp., acquired by Hologic Inc. (NASDAQ:HOLX), which revolutionized early detection of cervical cancer, and Exact Sciences (NASDAQ: EXAS), which pioneered the noninvasive early detection of colorectal cancer. He holds 37 patents, primarily in methods for early detection of cancer, and served as an instructor at MIT where he taught graduate-level courses on clinical trials. The two ThinPrep prototypes developed at Cytyc are displayed at the Smithsonian National Museum of American History.
  • Ron Andrews has more than 35 years of experience in the diagnostics industry. He served as CEO of two precision diagnostic companies, Clarient Inc., acquired by GE Healthcare, and Oncocyte Corp., and held corporate leadership positions at ThermoFisher/Life Technologies, Roche Molecular Diagnostics, and GE Healthcare. Through these experiences, Ron brings deep expertise in commercializing molecular diagnostics and is a dynamic and respected leader in the medical device industry.

“I’ve spent most of my career focused on the early detection of cancer and am excited and impressed by CellMax Life’s progress with its FirstSight blood test,” said Stan Lapidus. “The recent study data at ASCO GI 2023 displays the technology platform’s unique ability to detect colorectal cancer and advanced adenomas with a high degree of sensitivity, which is critical to the ultimate goal of eradicating this preventable cancer.”

“Colorectal cancer is one of the most preventable cancers, yet it is the second most common cause of death. A noninvasive screening blood test that detects both colorectal cancer and advanced adenomas has the potential to increase patient adherence for screening and in turn, decrease both incidence and mortality,” said Ron Andrews. “Being able to have a hand in the regulatory approval pathway for FirstSight, which has demonstrated high sensitivity in an intended use population, solidified my personal commitment to the company and its mission to change how we detect and manage cancer.”

For more information about CellMax Life and its FirstSight test, visit cellmaxlife.com.

About CellMax Life:

CellMax Life is a diagnostics company focused on cancer screening with proprietary technology for detecting precancerous and cancer cells and genomic aberrations in a single blood sample. CellMax Life is headquartered in Sunnyvale, California. For more information, visit http://www.cellmaxlife.com.

Share article on social media or email:

The Exceptional Women Alliance (EWA) announces selection of Janell Pittman, Chief Marketing and Digital Strategy Officer, MercyOne, as a Winter 2023 Awardee


Janell Pittman, Chief Marketing and Digital Strategy Officer, MercyOne

Janell Pittman, Chief Marketing and Digital Strategy Officer, MercyOne

“We are thrilled to welcome Janell! Her passion for building cultures, processes and systems to enable change and marketing will integrate a creative edge into our network of women,” said Larraine Segil, Chair & CEO of EWA.

The Exceptional Women Alliance (EWA) announces the selection of Winter 2023 awardee, Janell Pittman, Chief Marketing and Digital Strategy Officer, MercyOne. She led the teams behind launching the unified MercyOne brand and culture work which united 20,000 colleagues across more than 200 locations to work as one. She is currently responsible for advancing MercyOne’s marketing, communications, decision support and digital health strategy.

As an executive leader with a rich background in brand building, marketing, and change management, Ms. Pittman leads teams that are passionate about advancing the MercyOne brand both internally and externally. Her talents leading by influence are evidenced in her successes leading and implementing digital and telehealth strategies to advance MercyOne’s vision to set the standard for personalized and radically convenient care. She was recognized by Becker’s as one of 50 top chief digital strategy officers to know.

“We are thrilled to welcome Janell! Her passion for building cultures, processes and systems to enable change and marketing will integrate a creative edge into our network of women,” said Larraine Segil, Chair & CEO of EWA. “The breadth of expertise each awardee contributes is truly amazing and is what makes EWA so powerful!”

“This recognition for Janell is no surprise to those who know her. Her vision, expertise, influence, energy, versatility and collaboration are exceptional. She is highly respected by our Board of Directors, Executive Leadership Team peers, physician leaders, her teams, colleagues across our organization and beyond,” said Bob Ritz, President & CEO, MercyOne. “From her early impact at MercyOne, shaping our vision and strategic plan, to leading the development and deep implementation of a unified culture combined with launching the MercyOne brand to continued transformation by improving access to and delivery of health care through digital, her impact on our organization, colleagues and performance is tremendous.”

Before joining MercyOne in early 2017, Ms. Pittman spent nearly ten years at Meredith Corporation (MDP). At Meredith, she served as the vice president and general manager for digital brands, including AllRecipes, Meredith’s flagship Better Homes and Gardens, and Martha Stewart. There she was the hub for an extended team which included editors, site marketers, product management, developers, and subscription marketers. In addition to leading cross-functional teams to create world-class consumer experiences, she also led brands with challenging P&Ls to profitability.

Ms. Pittman also worked in brand management with Nestlé Purina and was a consultant for PricewaterhouseCoopers and IBM. She worked in North America and Europe, where she helped Fortune 100 and 500 clients across industries to improve profitability.

+++

The Exceptional Women Alliance (EWA) is an invitation only peer mentorship organization where high-potential, high-level Exceptional Women from across multiple industries are hand-selected and invested in, to grow, learn, share, and succeed. In addition to the achievement of significant success, the criteria for acceptance include character traits that are defining of the EWA Culture – Kindness, the Spirit of Generosity, Transparency, Gratitude and Willingness to Share their Networks. The Foundation is a powerhouse of peer-to-peer mentoring that provides guidance, deep connection, and leadership, propelling each woman to sustainable success – one woman at a time. The year-long program enables each member to be connected as alumnae for life in the ever-expanding EWA global network, as their fellow women leaders continue to move into positions of significance. Learn more at https://www.exceptionalwomenalliance.com/

Share article on social media or email:

Prominent Clinical Rheumatologist, Dr. John Beary, Joins NDA Partners as Expert Consultant


NDA Partners, A ProPharma Company.

Dr. Beary’s clinical expertise in rheumatology and immunology, in addition to his extensive knowledge of product development and regulation will be a valuable resource to companies developing new therapies in these areas.

NDA Partners’ Vice President and General Manager, Eric Fish, announced today that Dr. John Beary, an experienced clinical rheumatologist with more than 30 years of experience in clinical drug development and regulation, has joined the firm as an Expert Consultant. Dr. Beary’s expertise focuses on musculoskeletal/immunology/ rheumatology projects and throughout his career, he has served in academic, industry, and government roles including more than 40 years in clinical rheumatology and academic medicine.

Dr. Beary was formerly Professor of Clinical Medicine, Division of Immunology and Rheumatology with the University of Cincinnati where his research focused on rheumatoid arthritis, osteoporosis, and gout. Prior to this role, he served as Senior Medical Director, Musculoskeletal and Bone Research, Department of Worldwide Clinical Development, Procter & Gamble Pharmaceuticals and Senior Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America. As Senior Vice President of PhRMA, he was responsible for drug policy matters including drug safety, clinical development, and regulatory affairs and was Founding Member of the Steering Committee of the International Conference on Harmonization (ICH), and President of the Pharmaceutical Education and Research Institute (PERI).

Dr. Beary also served as Deputy Assistant Secretary of Defense (Health Affairs), Department of Defense in his early career, where he was responsible for oversight of DOD medical readiness, health benefits, and health information system programs. According to Dr. Carl Peck, Manager of NDA Partners’ drug development practice, “Dr. Beary’s clinical expertise in rheumatology and immunology, in addition to his extensive knowledge of product development and regulation will be a valuable resource to companies developing new therapies in these areas. We are pleased to welcome Dr. Beary to our team of Expert Consultants.”

Dr. Beary received his medical degree from Harvard Medical School, master’s in business administration from Georgetown University, and bachelor’s degree from the University of Notre Dame. He is board certified by American Board of Internal Medicine and completed his internal medicine residency with the Osler Medical Service at Johns Hopkins Hospital and rheumatology fellowship with the Hospital for Special Surgery and Cornell-New York Hospital Medical Center in New York City.

About NDA Partners

NDA Partners, a ProPharma company, is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.

Contact

Eric Fish, Vice President & General Manager

Office: 540-738-2550

FishEric@ndapartners.com

Share article on social media or email:

Team Novo Nordisk returns to the 2023 Tour de Pologne UCI World Tour


News Image

“2023 is an important year,” said Team Novo Nordisk’ General Manager, Vassili Davidenko, “Not only for our sponsor’s anniversary, but also for ten years of our partnership and wonderful work together. We are very happy to be able to celebrate this by returning to the Tour de Pologne.”

The third wild card for the 2023 Tour de Pologne UCI World Tour has officially been assigned to Team Novo Nordisk, the world’s first all-diabetes professional cycling team, which this year is celebrating the 100th anniversary of its title sponsor Novo Nordisk.

“2023 is an important year,” said Team Novo Nordisk’ General Manager, Vassili Davidenko. “Not only for our sponsor’s anniversary, but also for the ten years of our partnership and wonderful work together with them. We are very happy to be able to celebrate this by returning to the Tour de Pologne. We thank our friends at Lang Team for giving us the opportunity to compete with the best teams in the world, while inspiring all those with diabetes and showing them that it is possible to do sport even at a high level.”

A mission that has always been received with great sensitivity by the Tour de Pologne’ organization.

“It will be special to see the guys from Team Novo Nordisk racing on Polish roads,” commented Tour de Pologne’ Director, Czesław Lang. “As I have said many times, I am convinced that cycling has great power to bring people together and spread messages. The values of this team are noble and go beyond the concept of sport and applying to daily life. I hope that the Tour de Pologne, with its international audience, can contribute to raising awareness of the great goals that can be pursued by people living with this condition. Furthermore, Team Novo Nordisk has always been racing at the Tour de Pologne in an offensive and spectacular way.”

Share article on social media or email: